
News
Novo Nordisk AS: Our proposal offers Metsera shareholders highly attractive value, far exceeding the transaction proposed by Pfizer

Novo Nordisk AS: Our proposal offers Metsera shareholders highly attractive value, far exceeding the transaction proposed by Pfizer